title: Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
abstract: From July 1982 to August 1994, CEA levels were determined in 298 mammary tissue samples (30 benign, 242 primary breast cancer and 26 metastatic breast cancer). CEA serum levels were also evaluated in 30 patients with benign diseases, 153 patients with primary breast cancer and 26 patients with metastases. CEA tissue levels in both pellet and cytosol were significantly higher in samples from cancerous than from non malignant tissues (p < 0.0001), and higher in the pellet than in the cytosol (p < 0.0001). CEA in the pellet and cytosol were related to steroid receptors, with the highest levels being observed in ER+/PR+ tumors (p < 0.001). They were, however, not related to other pathological parameters such as tumor size or nodes. There was a correlation between CEA pellet and CEA serum in both patients with primary or metastatic tumors, with significantly higher CEA serum levels in patients with CEA pellet positivity than in those with CEA pellet negativity. CEA serum levels were a prognostic factor (DFS and OS) in the whole group as well as in node-positive and node-negative breast cancer patients. This prognostic value was only found in patients with CEA pellet positivity. In the follow-up of 143 NED patients, abnormal CEA serum levels rose prior to the diagnosis of relapse in 73% (29/40) of CEA pellet+ patients with distant recurrences but in only 9% (2/22) of CEA pellet- cases (p < 0.0001). In summary, CEA evaluation in tissue improves the CEA clinical application, selecting those patients whose serum CEA will be useful in the prognosis and early diagnosis of recurrence.
authors.affiliation: Laboratory of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinic, Medical School, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Molina
authors.forename: B
authors.initials: B
authors.lastname: Farrus
authors.forename: X
authors.initials: X
authors.lastname: Filella
authors.forename: J
authors.initials: J
authors.lastname: Jo
authors.forename: G
authors.initials: G
authors.lastname: Zanón
authors.forename: J
authors.initials: J
authors.lastname: Pahisa
authors.forename: M
authors.initials: M
authors.lastname: Latre
authors.forename: M
authors.initials: M
authors.lastname: Muñoz
authors.forename: A M
authors.initials: AM
authors.lastname: Ballesta
mesh_terms: D001940:Breast / Q000737:chemistry / Q000473:pathology; D001941:Breast Diseases / Q000097:blood / Q000473:pathology; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology* / Q000601:surgery; D002272:Carcinoembryonic Antigen / Q000032:analysis* / Q000097:blood; D003600:Cytosol / Q000737:chemistry / Q000473:pathology; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D008207:Lymphatic Metastasis; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies
chemical_list: D002272:Carcinoembryonic Antigen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone